97 results on '"Fuseau E"'
Search Results
2. EP42675, a synthetic parenteral dual‐action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs
3. First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action
4. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox–Gastaut syndrome using clinical trial simulation
5. Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCγRIII, in healthy volunteers
6. INVESTIGATION OF PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS BETWEEN CLAZOSENTAN AND NIMODIPINE IN ASAH PATIENTS: A POPULATION ANALYSIS: P292
7. Modélisation et essais cliniques en pédiatrie
8. Modelling and Clinical Trials in Paediatrics
9. Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine
10. CNS effects of sumatriptan and rizatriptan in healthy female volunteers
11. PHARMACOKINETICS (PK) OF SUMATRIPTAN NASAL SPRAY IN ADOLESCENT MIGRAINEURS.
12. META-ANALYSIS OF THE EXPOSURE/EFFICACY RELATIONSHIP FOR SUMATRIPTAN NASAL SPRAY
13. ACUTE TREATMENT OF MIGRAINE WITH ORAL NARATRIPTAN: THE CONCENTRATION-EFFICACY RELATIONSHIP
14. Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study
15. Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)
16. Modelling and Clinical Trials in Paediatrics
17. Modélisation et essais cliniques en pédiatrie
18. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration
19. 3-21-01 The pharmacokinetics of oral naratriptan in subjects with impaired renal or hepatic function
20. 1-21-09 Naratriptan oral pharmacokinetics in migraine subjects
21. 5-21-06 A pharmacokinetic-pharmacodynamic meta-analysis of blood pressure in healthy subjects
22. 2-21-08 The pharmacokinetics of oral naratriptan in healthy subjects
23. 3-21-02 Naratriptan oral pharmacokinetic-pharmacodynamic modelling of pain relief in migraine subjects
24. 1-21-10 Factors affecting oral naratriptan pharmacokinetics in migraine subjects
25. Safety, Tolerability, and Pharmacokinetics of Sumatriptan in Healthy Subjects Following Ascending Single Intranasal Doses and Multiple Intranasal Doses
26. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.
27. Nocturnal Profile of Growth Hormone Secretion during Sleep Induced by Zolpidem: A Double-Blind Study in Young Adults and Children
28. Pharmacokinetics of sumatriptan nasal spray in children.
29. Pharmacokinetics of sumatriptan nasal spray in adolescents.
30. Clinical pharmacokinetics of intranasal sumatriptan.
31. Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine.
32. Effect of Encapsulation of Absorption of Sumatriptan Tablets: Data from Healthy Volunteers and Patients During a Migraine
33. 50 GROWTH-HORMONE (GH) HOCTURNAL PROFILE DURING SLEEP INDUCED BY ZOLPIDEM: A DOUBLE BLIND STUDY VS PLACEBO
34. Population pharmacokinetics of nelfinavir (NFV) and its metabolite M8 when administered with ritonavir (RTV).
35. 50 GROWTHHORMONE GH HOCTURNAL PROFILE DURING SLEEP INDUCED BY ZOLPIDEM
36. Population pharmacokinetics of a triple-secured fibrinogen concentrate administered to afibrinogenaemic patients: Observed age- and body weight-related differences and consequences for dose adjustment in children.
37. Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage.
38. Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders.
39. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
40. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
41. Population pharmacokinetics of onercept in healthy subjects.
42. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.
43. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan.
44. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.
45. Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients.
46. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study.
47. Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling.
48. Reduction of hyperglycemia after oral glucose load by the new alpha 2-adrenergic receptor antagonist SL 84.0418 in healthy subjects.
49. Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine.
50. Effects of zolpidem versus diazepam and placebo on breathing control parameters in healthy human subjects.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.